Ono Pharmaceutical Future Growth

Future criteria checks 0/6

Ono Pharmaceutical's revenue and earnings are forecast to decline at 3.1% and 3.6% per annum respectively. EPS is expected to decline by 3.5% per annum. Return on equity is forecast to be 7.8% in 3 years.

Key information

-3.6%

Earnings growth rate

-3.54%

EPS growth rate

Pharmaceuticals earnings growth	8.6%
Revenue growth rate	-3.1%
Future return on equity	7.77%
Analyst coverage	Good
Last updated	02 Jun 2026

Recent future growth updates

Analysis Article • May 12

Analyst Estimates: Here's What Brokers Think Of Ono Pharmaceutical Co., Ltd. (TSE:4528) After Its Yearly Report

Investors in Ono Pharmaceutical Co., Ltd. ( TSE:4528 ) had a good week, as its shares rose 7.1% to close at JP¥2,479...

Analysis Article • Feb 05

Ono Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Ono Pharmaceutical Co., Ltd. ( TSE:4528 ) investors will be delighted, with the company turning in some strong numbers...

Analysis Article • Nov 01

Analysts Have Made A Financial Statement On Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Half-Year Report

Ono Pharmaceutical Co., Ltd. ( TSE:4528 ) investors will be delighted, with the company turning in some strong numbers...

Recent updates

Analysis Article • May 12

Analyst Estimates: Here's What Brokers Think Of Ono Pharmaceutical Co., Ltd. (TSE:4528) After Its Yearly Report

Investors in Ono Pharmaceutical Co., Ltd. ( TSE:4528 ) had a good week, as its shares rose 7.1% to close at JP¥2,479...

Analysis Article • Feb 05

Ono Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Ono Pharmaceutical Co., Ltd. ( TSE:4528 ) investors will be delighted, with the company turning in some strong numbers...

Analysis Article • Feb 02

A Look At The Intrinsic Value Of Ono Pharmaceutical Co., Ltd. (TSE:4528)

Key Insights Ono Pharmaceutical's estimated fair value is JP¥2,771 based on 2 Stage Free Cash Flow to Equity Current...

Analysis Article • Dec 02

Ono Pharmaceutical (TSE:4528) Has Affirmed Its Dividend Of ¥40.00

Ono Pharmaceutical Co., Ltd. ( TSE:4528 ) has announced that it will pay a dividend of ¥40.00 per share on the 22nd of...

Analysis Article • Nov 01

Analysts Have Made A Financial Statement On Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Half-Year Report

Ono Pharmaceutical Co., Ltd. ( TSE:4528 ) investors will be delighted, with the company turning in some strong numbers...

Analysis Article • Sep 19

Earnings and Revenue Growth Forecasts

TSE:4528 - Analysts future estimates and past financials data (JPY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2029	453,863	66,622	73,461	91,263	10
3/31/2028	443,466	59,834	76,387	96,095	11
3/31/2027	454,854	68,937	116,754	128,431	12
3/31/2026	515,785	69,767	83,551	136,821	N/A
12/31/2025	509,345	62,404	72,116	125,635	N/A
9/30/2025	503,668	48,495	49,061	102,300	N/A
6/30/2025	496,732	42,926	31,762	85,019	N/A
3/31/2025	486,871	50,047	74,469	82,459	N/A
12/31/2024	487,331	74,025	75,689	92,625	N/A
9/30/2024	484,298	95,127	91,943	108,662	N/A
6/30/2024	500,331	120,953	105,249	121,111	N/A
3/31/2024	502,672	127,977	89,831	110,660	N/A
12/31/2023	498,070	127,611	91,301	106,044	N/A
9/30/2023	489,199	124,875	97,371	115,354	N/A
6/30/2023	460,481	115,064	98,429	116,894	N/A
3/31/2023	447,187	112,723	145,113	159,610	N/A
12/31/2022	428,951	111,555	137,391	149,495	N/A
9/30/2022	403,985	96,568	93,387	102,437	N/A
6/30/2022	380,720	85,922	78,395	88,151	N/A
3/31/2022	361,361	80,519	49,552	61,829	N/A
12/31/2021	345,781	73,558	38,233	53,343	N/A
9/30/2021	332,887	81,866	60,412	83,032	N/A
6/30/2021	321,734	78,003	47,401	70,321	N/A
3/31/2021	309,284	75,425	53,684	73,977	N/A
12/31/2020	302,054	74,364	53,088	72,011	N/A
9/30/2020	293,886	66,737	55,742	70,596	N/A
6/30/2020	293,351	64,870	58,824	78,232	N/A
3/31/2020	292,420	59,704	51,712	74,157	N/A
12/31/2019	290,736	60,233	N/A	73,947	N/A
9/30/2019	293,247	55,510	N/A	66,058	N/A
6/30/2019	291,374	52,633	N/A	58,850	N/A
3/31/2019	288,634	51,539	N/A	66,774	N/A
12/31/2018	284,463	51,978	N/A	67,269	N/A
9/30/2018	284,785	57,919	N/A	61,700	N/A
6/30/2018	272,165	53,746	N/A	48,716	N/A
3/31/2018	261,836	50,284	N/A	15,727	N/A
12/31/2017	256,522	54,760	N/A	28,754	N/A
9/30/2017	248,517	53,884	N/A	40,205	N/A
6/30/2017	246,953	53,887	N/A	53,650	N/A
3/31/2017	244,797	55,793	N/A	74,450	N/A
12/31/2016	236,710	48,270	N/A	44,743	N/A
9/30/2016	207,707	36,225	N/A	32,972	N/A
6/30/2016	183,345	29,206	N/A	16,805	N/A
3/31/2016	160,284	24,979	N/A	12,842	N/A
12/31/2015	140,927	16,449	N/A	29,716	N/A
9/30/2015	143,697	21,568	N/A	31,169	N/A
6/30/2015	139,663	19,521	N/A	30,488	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4528's earnings are forecast to decline over the next 3 years (-3.6% per year).

Earnings vs Market: 4528's earnings are forecast to decline over the next 3 years (-3.6% per year).

High Growth Earnings: 4528's earnings are forecast to decline over the next 3 years.

Revenue vs Market: 4528's revenue is expected to decline over the next 3 years (-3.1% per year).

High Growth Revenue: 4528's revenue is forecast to decline over the next 3 years (-3.1% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4528's Return on Equity is forecast to be low in 3 years time (7.8%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/05 07:39
End of Day Share Price	2026/06/05 00:00
Earnings	2026/03/31
Annual Earnings	2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ono Pharmaceutical Co., Ltd. is covered by 19 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Atsushi Seki	Barclays
Koichi Mamegano	BofA Global Research
Hidemaru Yamaguchi	Citigroup Inc

Ono Pharmaceutical Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Analyst Estimates: Here's What Brokers Think Of Ono Pharmaceutical Co., Ltd. (TSE:4528) After Its Yearly Report

Ono Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Price target increased by 7.2% to JP¥1,929

Price target increased by 11% to JP¥1,896

Price target increased by 7.4% to JP¥1,709

Analysts Have Made A Financial Statement On Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Half-Year Report

Recent updates

Ono Pharmaceutical Co., Ltd. Announces Oral Presentation Of New Data From The Phase 2 Clinical Study Of ONO-4578 In Certain Gastric Cancers At The ASCO 2026 Annual Meeting

Ono Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Jul 31, 2026

Analyst Estimates: Here's What Brokers Think Of Ono Pharmaceutical Co., Ltd. (TSE:4528) After Its Yearly Report

Full year 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Ono Pharmaceutical Delivers Strong Profits for FY2025 While Guiding for Softer Revenue in FY2026

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 18, 2026

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 08, 2026

Ono Pharmaceutical Co., Ltd. Submits Application for Approval of Ripretinib in Japan

Upcoming dividend of JP¥40.00 per share

Now 20% undervalued

Ono Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Third quarter 2026 earnings: EPS and revenues exceed analyst expectations

A Look At The Intrinsic Value Of Ono Pharmaceutical Co., Ltd. (TSE:4528)

Price target increased by 7.2% to JP¥1,929

Price target increased by 11% to JP¥1,896

Price target increased by 7.4% to JP¥1,709

Ono Pharmaceutical (TSE:4528) Has Affirmed Its Dividend Of ¥40.00

First half dividend of JP¥40.00 announced

Ono Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 02, 2026

Analysts Have Made A Financial Statement On Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Half-Year Report

New major risk - Revenue and earnings growth

Now 21% undervalued

Ono Pharmaceutical Co., Ltd. Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study ofromVIMZA (Vomselinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025

Ono Pharmaceutical Co., Ltd. Announces Encouraging Efficacy Signals of ONO-2808, a S1P5 Receptor Agonist, in an Interim Analysis of Ongoing Phase 2 Clinical Trial in Patients with Multiple System Atrophy

Upcoming dividend of JP¥40.00 per share

Ono Pharmaceutical (TSE:4528) Will Pay A Dividend Of ¥40.00

Ono Pharmaceutical Co., Ltd. Receives European Commission Approval of ROMVIMZA (Vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Ono Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Oct 30, 2025

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Deciphera Pharmaceuticals, Llc Announces Positive Chmp Opinion Forromvimza™? (Vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (Tgct)

Ono Pharmaceutical's (TSE:4528) Dividend Will Be ¥40.00

Ono Pharmaceutical (TSE:4528) Will Pay A Dividend Of ¥40.00

Final dividend of JP¥40.00 announced

Full year 2025 earnings: EPS misses analyst expectations

Is Ono Pharmaceutical (TSE:4528) A Risky Investment?

New major risk - Revenue and earnings growth

Ono Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 01, 2025

Ono Pharmaceutical Co., Ltd. Presents Positive Results from Pivotal Trial in U.S. Patients with Relapsed or Refractory PCNSL At 2025 Asco Annual Meeting

Full year 2025 earnings: EPS misses analyst expectations

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 19, 2025

Consensus EPS estimates increase by 16%, revenue downgraded

Price target decreased by 11% to JP¥1,725

Upcoming dividend of JP¥40.00 per share

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 08, 2025

New major risk - Revenue and earnings growth

New minor risk - Profit margin trend

First half dividend of JP¥40.00 announced

Ono Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 03, 2025

Consensus EPS estimates fall by 17%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥40.00 per share

Ono Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Oct 31, 2024

Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Final dividend of JP¥40.00 announced

Consensus EPS estimates fall by 23%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Price target decreased by 10% to JP¥2,336

Ono Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) completed the acquisition of Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) from BlackRock, Inc. (NYSE:BLK), Deerfield Capital, L.P., Redmile Group, LLC Brightstar Associates, LLC and others.

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 10%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 20, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.